Table II.
Univariate analysis of the risk factors for poor overall survival and progression-free survival of patients with IHCC.
| Parameters | Overall survival
|
Progression-free survival
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age, ≥55 vs. <55 years | 1.000 (0.664-1.506) | 0.999 | 0.989 (0.660-1.482) | 0.956 |
| Sex, female vs. male | 0.928 (0.614-1.402) | 0.722 | 0.948 (0.630-1.425) | 0.797 |
| CA19-9, ≥37 U/ml vs. <37 U/ml | 1.069 (0.709-1.612) | 0.749 | 1.090 (0.726-1.637) | 0.676 |
| No. of tumors, multiple vs. single | 2.091 (1.267-3.451) | 0.004 | 1.945 (1.181-3.203) | 0.009 |
| Microvascular invasion, yes vs. no | 2.015 (1.327-3.060) | 0.001 | 1.998 (1.320-3.024) | 0.001 |
| Encapsulation, present vs. absent | 1.194 (0.785-1.816) | 0.407 | 1.217 (0.804-1.842) | 0.353 |
| Differentiation, poor/moderate vs. well | 1.681 (1.081-2.613) | 0.021 | 1.596 (1.035-2.462) | 0.034 |
| Tumor size, ≥5 vs. <5 cm | 1.384 (0.918-2.087) | 0.121 | 1.439 (0.958-2.163) | 0.079 |
| Lymphatic metastasis, yes vs. no | 3.130 (2.006-4.886) | <0.001 | 3.297 (2.114-5.142) | <0.001 |
| TNM stage, III/IV vs. I/II | 2.662 (1.749-4.053) | <0.001 | 2.616 (1.725-3.969) | <0.001 |
| ZEB1-AS1 expression, high vs. low | 1.211 (1.114-1.316) | <0.001 | 1.185 (1.093-1.285) | <0.001 |
ZEB1-AS1, lncRNA ZEB1 antisense 1; IHCC, intrahepatic cholangiocarcinoma.